Literature DB >> 25632841

Longitudinal changes in microperimetry and low luminance visual acuity in age-related macular degeneration.

Zhichao Wu1, Lauren N Ayton1, Chi D Luu1, Robyn H Guymer1.   

Abstract

IMPORTANCE: There is a need for more sensitive measures of disease in intermediate age-related macular degeneration (AMD) to evaluate novel interventions more effectively and expediently.
OBJECTIVE: To determine if microperimetry and low luminance visual acuity can detect functional changes over a short duration of follow-up. DESIGN, SETTING, AND PARTICIPANTS: Prospective longitudinal examination of 49 participants with consecutive AMD and 10 healthy participants in a research clinic from May 1, 2012, to December 31, 2013. Forty-one participants had intermediate AMD, 8 had nonfoveal geographic atrophy due to AMD. Participants underwent microperimetry examinations in 1 eye during a 12-month period at 6-month intervals for participants with AMD and at baseline and 12 months for control participants; low luminance visual acuity was performed at baseline and at 12 months for all participants. Changes in pathological features of intermediate AMD eyes were determined using side-by-side comparisons of color fundus photographs from the initial and final visit as remaining stable, progressed, or improved. MAIN OUTCOMES AND MEASURES: Microperimetric sensitivity and low luminance visual acuity.
RESULTS: A reduction in mean (SE) microperimetric pointwise sensitivity was identified at 12 months compared with the baseline for intermediate AMD eyes graded as stable (-0.31 dB [0.10 dB]; P = .003) or worsened (-0.42 dB [0.12 dB]; P < .001) and an improvement in mean (SE) pointwise sensitivity was identified in eyes graded as improved (1.13 dB [0.23 dB]; P < .001). A reduction in mean (SE) pointwise sensitivity was identified in eyes with nonfoveal geographic atrophy at both 6 months (-1.41 dB [0.22 dB]; P < .001) and 12 months compared with the baseline (-2.56 dB [0.22 dB]; P < .001) while a change in mean (SE) pointwise sensitivity was not identified over the 12-month period for control participants (-0.11 dB [0.11 dB]; P = .34). No changes in best-corrected visual acuity or low luminance visual acuity were identified in all groups over the 12-month period (P ≥ .07). CONCLUSIONS AND RELEVANCE: Microperimetry detected subtle changes in visual function over a 12-month period in eyes with intermediate AMD but visual acuity measures did not identify any such changes. These findings suggest that microperimetry is worth exploring as a method for assessing the efficacy of novel interventions for intermediate AMD potentially requiring a shorter duration of follow-up.

Entities:  

Mesh:

Year:  2015        PMID: 25632841     DOI: 10.1001/jamaophthalmol.2014.5963

Source DB:  PubMed          Journal:  JAMA Ophthalmol        ISSN: 2168-6165            Impact factor:   7.389


  38 in total

Review 1.  [Development and validation of novel clinical endpoints in intermediate age-related macular degeneration in MACUSTAR].

Authors:  Jan H Terheyden; Robert P Finger; Steffen Schmitz-Valckenberg; Hansjürgen Agostini; Claudia Dahlke; Laura Kuehlewein; Gabriele E Lang; Daniel Pauleikhoff; Armin Wolf; Michael K Boettger; Ulrich F O Luhmann; Friedrich Asmus; Frank G Holz
Journal:  Ophthalmologe       Date:  2019-12       Impact factor: 1.059

2.  VISUAL FUNCTION MEASURES IN EARLY AND INTERMEDIATE AGE-RELATED MACULAR DEGENERATION.

Authors:  Arthika Chandramohan; Sandra S Stinnett; John T Petrowski; Stefanie G Schuman; Cynthia A Toth; Scott W Cousins; Eleonora M Lad
Journal:  Retina       Date:  2016-05       Impact factor: 4.256

3.  Long-term longitudinal modifications in mesopic microperimetry in early and intermediate age-related macular degeneration.

Authors:  Stela Vujosevic; Porzia Pucci; Margerita Casciano; Evelyn Longhin; Enrica Convento; Silvia Bini; Edoardo Midena
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-08-31       Impact factor: 3.117

Review 4.  Microperimetry in age: related macular degeneration.

Authors:  E Midena; E Pilotto
Journal:  Eye (Lond)       Date:  2017-03-03       Impact factor: 3.775

5.  Longitudinal Study of Visual Function in Dry Age-Related Macular Degeneration at 12 Months.

Authors:  S Tammy Hsu; Atalie C Thompson; Sandra S Stinnett; Ulrich F O Luhmann; Lejla Vajzovic; Anupama Horne; Stefanie G Schuman; Cynthia A Toth; Scott W Cousins; Eleonora M Lad
Journal:  Ophthalmol Retina       Date:  2019-03-21

Review 6.  Microperimetry for geographic atrophy secondary to age-related macular degeneration.

Authors:  Karl G Csaky; Praveen J Patel; Yasir J Sepah; David G Birch; Diana V Do; Michael S Ip; Robyn H Guymer; Chi D Luu; Shamika Gune; Hugh Lin; Daniela Ferrara
Journal:  Surv Ophthalmol       Date:  2019-01-28       Impact factor: 6.048

Review 7.  Biochemical Measurements of Free Opsin in Macular Degeneration Eyes: Examining the 11-CIS Retinal Deficiency Hypothesis of Delayed Dark Adaptation (An American Ophthalmological Society Thesis).

Authors:  Anne Hanneken; Thomas Neikirk; Jennifer Johnson; Masahiro Kono
Journal:  Trans Am Ophthalmol Soc       Date:  2017-08-22

8.  Visual Function Metrics in Early and Intermediate Dry Age-related Macular Degeneration for Use as Clinical Trial Endpoints.

Authors:  Kimberly J Cocce; Sandra S Stinnett; Ulrich F O Luhmann; Lejla Vajzovic; Anupama Horne; Stefanie G Schuman; Cynthia A Toth; Scott W Cousins; Eleonora M Lad
Journal:  Am J Ophthalmol       Date:  2018-03-15       Impact factor: 5.258

9.  Identifying the content for an item bank and computerized adaptive testing system to measure the impact of age-related macular degeneration on health-related quality of life.

Authors:  Eva K Fenwick; Ester P X Lee; Ryan E K Man; Kam Chun Ho; Raymond P Najjar; Dan Milea; Kelvin Y C Teo; Anna C S Tan; Shu Yen Lee; Ian Yew San Yeo; Gavin S W Tan; Ranjana Mathur; Tien Yin Wong; Chui Ming Gemmy Cheung; Ecosse L Lamoureux
Journal:  Qual Life Res       Date:  2021-09-25       Impact factor: 4.147

Review 10.  Clinical Perspectives and Trends: Microperimetry as a Trial Endpoint in Retinal Disease.

Authors:  Yesa Yang; Hannah Dunbar
Journal:  Ophthalmologica       Date:  2021-02-10       Impact factor: 3.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.